NPAS2 and prostate cancer: In order to further explore the relationship between NPAS2 and prostate cancer, a study by Chu et al. compared the association between 240 circadian rhythm gene single nucleotide polymorphisms (SNPs) and prostate cancer risk in 450 patients treated with finasteride (an androgen biological activation inhibitor) and 422 controls.